AU660420B2 - Method for treating immune system dysfunctions - Google Patents

Method for treating immune system dysfunctions Download PDF

Info

Publication number
AU660420B2
AU660420B2 AU84333/91A AU8433391A AU660420B2 AU 660420 B2 AU660420 B2 AU 660420B2 AU 84333/91 A AU84333/91 A AU 84333/91A AU 8433391 A AU8433391 A AU 8433391A AU 660420 B2 AU660420 B2 AU 660420B2
Authority
AU
Australia
Prior art keywords
immune system
lys
dynorphin
patient
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU84333/91A
Other languages
English (en)
Other versions
AU8433391A (en
Inventor
Nancy M. Lee
Horace H Loh
S Ramakrishnan
Sabita Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU8433391A publication Critical patent/AU8433391A/en
Application granted granted Critical
Publication of AU660420B2 publication Critical patent/AU660420B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AU84333/91A 1990-08-03 1991-08-02 Method for treating immune system dysfunctions Ceased AU660420B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56239390A 1990-08-03 1990-08-03
US562393 1990-08-03
PCT/US1991/005518 WO1992002547A1 (en) 1990-08-03 1991-08-02 Method for treating immune system dysfunctions

Publications (2)

Publication Number Publication Date
AU8433391A AU8433391A (en) 1992-03-02
AU660420B2 true AU660420B2 (en) 1995-06-29

Family

ID=24246112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU84333/91A Ceased AU660420B2 (en) 1990-08-03 1991-08-02 Method for treating immune system dysfunctions

Country Status (5)

Country Link
EP (1) EP0541694A1 (enExample)
JP (1) JPH06501930A (enExample)
AU (1) AU660420B2 (enExample)
CA (1) CA2088679A1 (enExample)
WO (1) WO1992002547A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817628A (en) * 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
US20190241660A1 (en) * 2017-12-05 2019-08-08 Intendet Services, Llc Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537878A (en) * 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system
US4757049A (en) * 1981-10-05 1988-07-12 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system of patients with aids
US4801614A (en) * 1981-10-05 1989-01-31 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537878A (en) * 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system
US4757049A (en) * 1981-10-05 1988-07-12 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system of patients with aids
US4801614A (en) * 1981-10-05 1989-01-31 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells

Also Published As

Publication number Publication date
CA2088679A1 (en) 1992-02-04
JPH06501930A (ja) 1994-03-03
AU8433391A (en) 1992-03-02
WO1992002547A1 (en) 1992-02-20
EP0541694A4 (enExample) 1994-03-09
EP0541694A1 (en) 1993-05-19

Similar Documents

Publication Publication Date Title
Shavit et al. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity
Ben-Eliyahu et al. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and β-adrenoceptors
Old Tumor necrosis factor
CA2137916A1 (en) Des-tyr dynorphin analogues
Dafny et al. Immune response products alter CNS acitivity: Interferon modulates central opioid function
JPH08502024A (ja) インターフェロン−αとヒスタミン、セロトニン、アミン類または相当するレセプター活性を有する物質とを含有するナチュラルキラー細胞（ＮＫ細胞）活性化用製剤
CA2199730A1 (en) Protection of hemopoietic cells during chemotherapy or radiotherapy
Saphier et al. α-Interferon inhibits adrenocortical secretion via μ1-opioid receptors in the rat
AU2005307814A1 (en) Histone deacetylase inhibitors and methods of use
US5534495A (en) Treatment of non-HIV neuropathic pain syndromes
WO1997015595A1 (en) Method of mobilizing hematopoietic stem cells
Fride et al. Immunoenhancing effects of alprazolam in mice
AU8433391A (en) Method for treating immune system dysfunctions
US4801614A (en) Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells
Bayer et al. Tolerance and crosstolerance to the suppressive effects of cocaine and morphine on lymphocyte proliferation
Greenberg et al. Neurohormonal modulation of natural resistance to a murine lymphoma
US5807827A (en) Des-Tyr dynorphin analogues
Roy et al. Dynorphin blocks opioid inhibition of macrophage-colony stimulating factor-induced proliferation of bone marrow cells
Nicoletti et al. Prevention of cyclophosphamide‐induced diabetes in the NOD/WEHI mouse with deoxyspergualin
WO1993002692A1 (en) Method of combatting hiv infections
KR102398968B1 (ko) 조혈 줄기세포의 가동을 위한 물질-p의 배합 요법
Loh et al. Effects of opioids on proliferation of mature and immature immune cells
US4929640A (en) Medicaments intended for combined use in the improvement of lymphocyte function
JPH06504767A (ja) Ｂ−細胞悪性疾患の治療のための薬剤組成物
Rotiroti Giuseppe Nisticò, Giovanbattista De Sarro, and